- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00779987
Autologous Serum Efficacy Study in Patients With Severe Dry Eye
December 2, 2008 updated by: University of Chile
The purpose of this study is to compare the reduction in symptomatology of patients with severe dry eye treated with autologous serum and conventional artificial tears.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Severe dry eye remains an important and frequent eye disease, that reflects in a severe impairment of the patient´s life quality.
Up to date there is no ideal therapy for this condition.
Few studies have reported some kind of improvement in different parameters related to dry eye with the use of autologous serum, but no one has considered the patient´s symptoms with a systematic and validated evaluation method.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Region Metropolitana
-
Santiago, Region Metropolitana, Chile
- University of Chile Clinical Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 18 years
- Severe Dry Eye, as defined by a OSDI score > or = 40
Plus:
- Tear Break Up Time (TBUT) < 5 seconds
- Cornea-conjunctival epithelial defects measured by Fluorescein staining and evaluation using the Oxford score.
Exclusion Criteria:
- No dry eye associated ocular disease
- Unable to comply protocol
- Severe anemia
- Previous use of autologous serum
- Concomitant use of other topical ocular drug
- Hypersensibility to any proposed interventions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Autologous serum -Systane
Crossover arm starting with autologous serum for 2 weeks.
After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
|
20% autologous serum solution used four times a day for two weeks.
Then 0.9% sodium chloride four times a day for one week.
Finally, Systane (r) four times a day for two weeks.
|
OTHER: Systane- Autologous serum
Crossover arm starting with artificial tears (Systane) for 2 weeks.
After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
|
Systane (r) four times a day for two weeks.
Then 0.9% sodium chloride used four times a day for one weeks.
Finally, 20% autologous serum solution four times a day for two week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To compare the score reduction in the Ocular Surface Disease Index (OSDI) between patients treated with autologous serum and conventional artificial tears.
Time Frame: 5 weeks
|
5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To compare variations in objective eye measurements, such as Tear Break Up Time and corneal-conjunctival staining according to the Oxford Score, in patients treated with autologous serum and conventional artificial tears.
Time Frame: 5 weeks
|
5 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Cristhian A Urzua, MD, University of Chile
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (ACTUAL)
December 1, 2008
Study Completion (ACTUAL)
December 1, 2008
Study Registration Dates
First Submitted
October 22, 2008
First Submitted That Met QC Criteria
October 22, 2008
First Posted (ESTIMATE)
October 24, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
December 3, 2008
Last Update Submitted That Met QC Criteria
December 2, 2008
Last Verified
October 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AP261
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on Autologous serum - Systane
-
Pontificia Universidad Catolica de ChileHospital Dr Sotero del RioUnknownDry Eye | Keratoconjunctivitis Sicca | Lacrimal Apparatus Diseases | Conjunctival Diseases | Keratitis | Corneal Diseases | Sjogren's SyndromeChile
-
Eskisehir Osmangazi UniversityCompletedUrticaria | Respiratory Allergic DiseasesTurkey
-
University of Turin, ItalyRecruiting
-
E-DA HospitalCompletedCorneal DiseasesTaiwan
-
King Khaled Eye Specialist HospitalCompleted
-
National Taiwan University HospitalCompletedDiabetic Retinopathy | Corneal Epithelial Defect | Penetrating KeratoplastyTaiwan
-
Anita Syla LokajEnrolling by invitation
-
Chonnam National University HospitalCompletedDry Eye SyndromeKorea, Republic of
-
Sanquin Research & Blood Bank DivisionsRadboud University Medical CenterCompleted